elsamitrucin
Small moleculeexperimental
Elsamitrucin is a drug used in chemotherapy. Elsamitrucin is chemically related to chartreusin. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00090090)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- DNA topoisomerase IINHIBITOR
TOP1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H]1[C@@H](N)[C@@H](O[C@H]2[C@H](Oc3cccc4c(O)c5c(=O)oc6ccc(C)c7c(=O)oc(c34)c5c67)O[C@H](C)[C@H](O)[C@]2(C)O)O[C@H](C)[C@@H]1O- Mol. weight
- 653.64 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaElsamitrucin ↗
- ChEMBLCHEMBL2106409 ↗
Also known as
- bbm 2478a
- bbm-2478a
- bbm-2478a
- bbm-2478a
- benzo(h)(1)benzopyrano(5,4,3-cde)(1)benzopyran-5,12-dione, 10-((2-o-(2-amino-2,6-dideoxy-3-o-methyl-alpha-d-galactopyranosyl)-6-deoxy-3-c-methyl-beta-d-galactopyranosyl)oxy)-6-hydroxy-1-methyl-
- bmy 28090
- bmy-28090
- bmy-28090
- bmy-28090
- elsamicin a
- elsamitrucin
- elsamitrucin
- elsamitrucin
- elsamitrucin
- elsamitrucin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00184080 | Phase 2 | May 1, 2004 | Spectrum Pharmaceuticals, University of Southern California |
| NCT00090090 | Phase 2 | Apr 1, 2004 | Spectrum Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spectrum Pharmaceuticals | For profit | 2 | 1 | 1 | 2004 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2004 |
2 organizations
Page 1 / 1